Literature DB >> 34409542

Preoperative Estimated Risk of Microvascular Invasion is Associated with Prognostic Differences Following Liver Resection Versus Radiofrequency Ablation for Early Hepatitis B Virus-Related Hepatocellular Carcinoma.

Shilei Bai1,2, Pinghua Yang3, Zhihao Xie1, Jun Li1, Zhengqing Lei1,4, Yong Xia1, Guojun Qian5, Baohua Zhang6, Timothy M Pawlik7, Wan Yee Lau1,8, Feng Shen9.   

Abstract

OBJECTIVES: The aim of this study was to examine prognostic differences between liver resection (LR) and percutaneous radiofrequency ablation (PRFA) for hepatocellular carcinoma (HCC) based on preoperative predicted microvascular invasion (MVI) risk.
METHODS: Data on consecutive patients who underwent LR (n = 1344) or PRFA (n = 853) for hepatitis B virus-related HCC within the Milan criteria (MC) were analyzed. A preoperative nomogram was used to estimate MVI risk. Overall survival (OS), time to recurrence, and patterns of recurrence were compared using propensity score matching.
RESULTS: The concordance indices of the nomogram to predict MVI were 0.813 and 0.781 among LR patients with HCC within the MC or ≤ 3 cm, respectively. LR and PRFA resulted in similar 5-year recurrence and OS for patients with nomogram-predicted low-risk of MVI. LR provided better 5-year recurrence and OS versus PRFA for patients with high-risk of MVI (71.6% vs. 80.7%, p = 0.013; 47.9% vs. 34.0%, p = 0.002, for HCC within the MC; 62.3% vs. 78.8%, p = 0.020; 63.6% vs. 38.3%, p = 0.015, for HCC ≤ 3 cm). Among high-risk patients, LR was associated with lower recurrence and improved OS compared with PRFA, on multivariate analysis [hazard ratio (HR) 0.78, 95% confidence interval (CI) 0.63-0.97, and HR 0.68, 95% CI 0.52-0.88, for HCC within the MC; HR 0.51, 95% CI 0.32-0.81, and HR 0.47, 95% CI 0.26-0.84, for HCC ≤ 3 cm], and resulted in less early and local recurrence than PRFA (42.4% vs. 54.8%, p = 0.007, and 31.2% vs. 46.1%, p = 0.007, for HCC within the MC; 27.9% vs. 50.8%, p = 0.016, and 15.6% vs. 39.5%, p = 0.046, for HCC ≤ 3 cm).
CONCLUSIONS: LR was oncologically superior over PRFA for early HCC patients with predicted high-risk of MVI. LR was associated with better local disease control than PRFA in these patients.
© 2021. Society of Surgical Oncology.

Entities:  

Mesh:

Year:  2021        PMID: 34409542     DOI: 10.1245/s10434-021-09901-3

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  40 in total

1.  A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria.

Authors:  Jiwei Huang; Lvnan Yan; Zheyu Cheng; Hong Wu; Liang Du; Jinzhou Wang; Yinglong Xu; Yong Zeng
Journal:  Ann Surg       Date:  2010-12       Impact factor: 12.969

2.  Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice?

Authors:  Tito Livraghi; Franca Meloni; Michele Di Stasi; Emanuela Rolle; Luigi Solbiati; Carmine Tinelli; Sandro Rossi
Journal:  Hepatology       Date:  2008-01       Impact factor: 17.425

3.  Small Hepatocellular Carcinoma: Radiofrequency Ablation versus Nonanatomic Resection--Propensity Score Analyses of Long-term Outcomes.

Authors:  Tae Wook Kang; Jong Man Kim; Hyunchul Rhim; Min Woo Lee; Young-sun Kim; Hyo Keun Lim; Dongil Choi; Kyoung Doo Song; Choon Hyuck David Kwon; Jae-Won Joh; Seung Woon Paik; Yong Han Paik; Joong Hyun Ahn
Journal:  Radiology       Date:  2015-02-16       Impact factor: 11.105

4.  Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases.

Authors:  Jorge A Marrero; Laura M Kulik; Claude B Sirlin; Andrew X Zhu; Richard S Finn; Michael M Abecassis; Lewis R Roberts; Julie K Heimbach
Journal:  Hepatology       Date:  2018-08       Impact factor: 17.425

5.  Randomized clinical trial of hepatic resection versus radiofrequency ablation for early-stage hepatocellular carcinoma.

Authors:  K K C Ng; K S H Chok; A C Y Chan; T T Cheung; T C L Wong; J Y Y Fung; J Yuen; R T P Poon; S T Fan; C M Lo
Journal:  Br J Surg       Date:  2017-11-01       Impact factor: 6.939

6.  A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma.

Authors:  Kai Feng; Jun Yan; Xiaowu Li; Feng Xia; Kuansheng Ma; Shuguang Wang; Ping Bie; Jiahong Dong
Journal:  J Hepatol       Date:  2012-05-23       Impact factor: 25.083

7.  Radiofrequency ablation as an alternative to hepatic resection for single small hepatocellular carcinomas.

Authors:  G-A Kim; J H Shim; M-J Kim; S Y Kim; H J Won; Y M Shin; P N Kim; K-H Kim; S-G Lee; H C Lee
Journal:  Br J Surg       Date:  2015-11-17       Impact factor: 6.939

8.  Long-term effectiveness of resection and radiofrequency ablation for single hepatocellular carcinoma ≤3 cm. Results of a multicenter Italian survey.

Authors:  Maurizio Pompili; Antonio Saviano; Nicoletta de Matthaeis; Alessandro Cucchetti; Francesco Ardito; Bruno Federico; Franco Brunello; Antonio D Pinna; Antonio Giorgio; Stefano M Giulini; Ilario De Sio; Guido Torzilli; Fabio Fornari; Lorenzo Capussotti; Alfredo Guglielmi; Fabio Piscaglia; Luca Aldrighetti; Eugenio Caturelli; Fulvio Calise; Gennaro Nuzzo; Gian Ludovico Rapaccini; Felice Giuliante
Journal:  J Hepatol       Date:  2013-03-22       Impact factor: 25.083

9.  A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma.

Authors:  Min-Shan Chen; Jin-Qing Li; Yun Zheng; Rong-Ping Guo; Hui-Hong Liang; Ya-Qi Zhang; Xiao-Jun Lin; Wan Y Lau
Journal:  Ann Surg       Date:  2006-03       Impact factor: 12.969

Review 10.  Epidemiology and surveillance for hepatocellular carcinoma: New trends.

Authors:  Amit G Singal; Pietro Lampertico; Pierre Nahon
Journal:  J Hepatol       Date:  2020-02       Impact factor: 25.083

View more
  1 in total

1.  LINC00665 regulates hepatocellular carcinoma by modulating mRNA via the m6A enzyme.

Authors:  Ming Lei; Xinghua Du; Xiaokai Li; Fuke Wang; Ling Gu; Feng Guo
Journal:  Open Life Sci       Date:  2022-02-11       Impact factor: 0.938

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.